JP2008513529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513529A5 JP2008513529A5 JP2007532821A JP2007532821A JP2008513529A5 JP 2008513529 A5 JP2008513529 A5 JP 2008513529A5 JP 2007532821 A JP2007532821 A JP 2007532821A JP 2007532821 A JP2007532821 A JP 2007532821A JP 2008513529 A5 JP2008513529 A5 JP 2008513529A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- concentrate
- prevention
- polyol
- suppression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 239000012141 concentrate Substances 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- -1 2,4,6-triisopropylphenylsulfonyl Chemical group 0.000 claims 5
- 229920005862 polyol Polymers 0.000 claims 5
- 150000003077 polyols Chemical class 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- DOGXZGWWONUGJF-QMMMGPOBSA-N (2S)-2-[[amino-(hydroxyamino)methylidene]amino]-3-phenylpropanoic acid Chemical class ONC(=N)N[C@H](C(O)=O)CC1=CC=CC=C1 DOGXZGWWONUGJF-QMMMGPOBSA-N 0.000 claims 1
- MVTHUEOHHHQQKY-QMMMGPOBSA-N (2s)-2-(diaminomethylideneamino)-3-phenylpropanoic acid Chemical class NC(N)=N[C@H](C(O)=O)CC1=CC=CC=C1 MVTHUEOHHHQQKY-QMMMGPOBSA-N 0.000 claims 1
- KIPIDQBXOKPNDP-QMMMGPOBSA-N (2s)-2-[(diaminomethylideneamino)-hydroxyamino]-3-phenylpropanoic acid Chemical class NC(N)=NN(O)[C@H](C(O)=O)CC1=CC=CC=C1 KIPIDQBXOKPNDP-QMMMGPOBSA-N 0.000 claims 1
- MJIDYLIDXWGFRN-QMMMGPOBSA-N (2s)-2-[2-(diaminomethylidene)hydrazinyl]-3-phenylpropanoic acid Chemical class NC(=N)NN[C@H](C(O)=O)CC1=CC=CC=C1 MJIDYLIDXWGFRN-QMMMGPOBSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 201000002543 age related macular degeneration 2 Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007974 sodium acetate buffer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000005760 tumorsuppression Effects 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004045720.4 | 2004-09-21 | ||
| DE102004045720A DE102004045720A1 (de) | 2004-09-21 | 2004-09-21 | Stabile Dosierungsform von Phenylalanin-Derivaten |
| PCT/EP2005/010143 WO2006032461A1 (de) | 2004-09-21 | 2005-09-20 | Stabile dosierungsform von phenylalanin-derivaten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513529A JP2008513529A (ja) | 2008-05-01 |
| JP2008513529A5 true JP2008513529A5 (https=) | 2008-08-14 |
| JP5054529B2 JP5054529B2 (ja) | 2012-10-24 |
Family
ID=35429536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532821A Expired - Fee Related JP5054529B2 (ja) | 2004-09-21 | 2005-09-20 | フェニルアラニン誘導体の安定な投与形 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9089532B2 (https=) |
| EP (1) | EP1799265B1 (https=) |
| JP (1) | JP5054529B2 (https=) |
| KR (1) | KR101228385B1 (https=) |
| CN (1) | CN1993144B (https=) |
| AT (1) | ATE480260T1 (https=) |
| AU (1) | AU2005287582B2 (https=) |
| BR (1) | BRPI0515533B8 (https=) |
| CA (1) | CA2580639C (https=) |
| DE (2) | DE102004045720A1 (https=) |
| ES (1) | ES2347670T3 (https=) |
| MX (1) | MX2007000399A (https=) |
| RU (1) | RU2358736C2 (https=) |
| WO (1) | WO2006032461A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| CN117695284B (zh) | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA986594B (en) | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
| US6624169B1 (en) * | 1998-07-20 | 2003-09-23 | Wilex Biotechnology Gmbh | Urokinase inhibitors |
| SI1453852T1 (sl) * | 2001-12-12 | 2007-06-30 | Wilex Ag | Selektivni arilgvanidinpeptidi kot inhibitorji urokinaze |
| AU2003219039A1 (en) * | 2002-03-11 | 2003-09-22 | Curacyte Ag | Urokinase inhibitors, production and use thereof |
| DE10225876A1 (de) * | 2002-06-11 | 2003-12-24 | Wilex Ag | Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren |
| WO2004011449A2 (de) * | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur herstellung von phenylalanin-derivaten |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
-
2004
- 2004-09-21 DE DE102004045720A patent/DE102004045720A1/de not_active Withdrawn
-
2005
- 2005-09-20 BR BRPI0515533A patent/BRPI0515533B8/pt not_active IP Right Cessation
- 2005-09-20 CN CN2005800256252A patent/CN1993144B/zh not_active Expired - Fee Related
- 2005-09-20 EP EP05786251A patent/EP1799265B1/de not_active Expired - Lifetime
- 2005-09-20 WO PCT/EP2005/010143 patent/WO2006032461A1/de not_active Ceased
- 2005-09-20 ES ES05786251T patent/ES2347670T3/es not_active Expired - Lifetime
- 2005-09-20 JP JP2007532821A patent/JP5054529B2/ja not_active Expired - Fee Related
- 2005-09-20 RU RU2007115064/15A patent/RU2358736C2/ru active
- 2005-09-20 US US11/631,891 patent/US9089532B2/en active Active
- 2005-09-20 CA CA2580639A patent/CA2580639C/en not_active Expired - Fee Related
- 2005-09-20 KR KR1020077005447A patent/KR101228385B1/ko not_active Expired - Fee Related
- 2005-09-20 DE DE502005010237T patent/DE502005010237D1/de not_active Expired - Lifetime
- 2005-09-20 AU AU2005287582A patent/AU2005287582B2/en not_active Ceased
- 2005-09-20 MX MX2007000399A patent/MX2007000399A/es active IP Right Grant
- 2005-09-20 AT AT05786251T patent/ATE480260T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105534970B (zh) | 高浓度奥洛他定眼用组合物 | |
| Sosnik et al. | New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery | |
| US20040110828A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
| TWI574692B (zh) | 偏亞砷酸鈉於治療白血病及淋巴瘤之用途 | |
| JP2013513612A5 (https=) | ||
| JP7440630B2 (ja) | ウルソデオキシコール酸の注射用組成物 | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| CN104349780A (zh) | 含有吡罗昔康或其药学上可接受的盐和透明质酸或其药学上可接受的盐的稳定液体药学组合物及其制造方法 | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| ES2546672T3 (es) | Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona | |
| CN105963244A (zh) | 注射用青蒿琥酯制剂及其应用 | |
| WO2012042197A2 (en) | Low dose pharmaceutical composition | |
| PT1224188E (pt) | Composição de administração nasal que compreende o sal metanossulfonato de morfina e quitosano | |
| EP1206256B1 (en) | Combination therapy using pentafluorobenzenesulfonamide and platin compound | |
| TW200800270A (en) | Factor Xa inhibitor formulation and method | |
| JP2008513529A5 (https=) | ||
| JP6498610B2 (ja) | カバジタキセル組成物 | |
| MX2008010394A (es) | Tratamientos antivirales intravenosos. | |
| EP4076442A1 (en) | Pharmaceutical composition of cyclooxygenase - 2 inhibitors | |
| CN103462891B (zh) | 一种异硫氰酸烯丙酯胶束制剂 | |
| US20150057305A1 (en) | Pharmaceutical composition | |
| RU2007115064A (ru) | Стойкая лекарственная форма из производных фенилаланина | |
| RU2279277C2 (ru) | Лечение разделенными дозами агентов с сосудоразрушающей активностью | |
| JP2025522933A (ja) | メルファランを含む安定した液体医薬組成物 | |
| JPH10251151A (ja) | 癌転移阻害剤 |